1stOncology™: Cancer Intelligence Service – Page 4803 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ImmuneOnco Biopharmaceuticals’ IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting

On March 21, 2023 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") reported that the company will present the preclinical research data of IMM47 (CD24 antibody), IMM40H (CD70 antibody), IMM2520 (CD47×PD-L1), and IMM2902 (CD47×Her2) in the form of posters at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2023) Annual Meeting in Orlando, Florida from April 14th to 19th (Press release, ImmuneOnco Biopharma, MAR 21, 2023, View Source [SID1234655687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

HLB Life, Phase 3 Clinical Trial Plan for ‘Pyrotinib’ for Breast Cancer Approved

On March 21, 2023 HLB Life Science reported that it received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial plan for the anticancer drug ‘Pyrotinib’ (Press release, HLB Life Science, MAR 21, 2023, View Source;word=&page=1&v=381 [SID1234649274]).

The title of the clinical trial is ‘A randomized, active-controlled, open-label, multi-center phase 3 clinical trial to evaluate the efficacy and safety of Pyrotinib + Capecitabine combination compared to Lapatinib + Capecitabine combination in patients with HER2-positive metastatic or recurrent breast cancer’. The clinical trial will be conducted on 204 patients in 11 hospitals in Korea (total of 12 hospitals) excluding Seoul National University Hospital. (Clinical period: 36 months from the date of approval by the Institutional Review Board)

The company plans to confirm the progression-free survival period (PFS, primary endpoint) through this clinical trial.

Pyrotinib is a small molecule compound independently developed by Hengrui Pharmaceutical of China, and is an oral targeted anticancer drug targeting EGFR/HER2/HER4. In 2020, it received official approval in China as a second-line treatment for HER2 metastatic breast cancer. In

2020, HLB Life Science signed an exclusive licensing agreement for Pyrotinib in Korea with Hangseo Pharmaceutical, and has exclusive rights to the clinical development and sales of Pyrotinib as a treatment for various cancers, including breast cancer and lung cancer, in Korea.

HLB Life Science applied for the clinical trial to the Ministry of Food and Drug Safety on July 29, 2022.

Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs

On March 21, 2023 EpicentRx Inc. ("EpicentRx"), a clinical stage biopharmaceutical company, reported the publication of a review article on its small molecule, RRx-001, a direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegenerative diseases and other inflammatory conditions (Press release, EpicentRx, MAR 21, 2023, View Source [SID1234629107]). The article is entitled, A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

This is the first publication from the collaboration between EpicentRx and Associate Professor Richard Gordon’s team based at the Queensland University of Technology’s Centre for Microbiome Research (CMR) and the Translational Research Institute (TRI). Dr. Gordon is an internationally recognized expert on inflammasome signaling in neurodegenerative diseases. EpicentRx and Dr. Gordon’s team were awarded research grants from the Michael J. Fox Foundation (MJFF), Shake It Up Australia Foundation, and Fight MND to study the neuroprotective effects of RRx-001 in Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS).

RRx-001 is one of the most advanced direct NLRP3 inflammasome inhibitors in clinical development and has been evaluated in over 300 multimorbid cancer patients both alone and in combination with other therapies. Currently in a Phase 3 trial for the treatment of small cell lung cancer, RRx-001 is also in late-stage development as an anti-mucositis agent in head and neck cancer and as a medical countermeasure against acute radiation syndrome (ARS) in the event of nuclear fallout. RRx-001 has been evaluated in multiple independent studies for conditions where immune and inflammasome activation contribute to disease pathology. These include cancer, myocardial infarction, pulmonary hypertension, acute kidney injury, acute radiation syndrome (ARS), malaria, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.

Lead author Dr. Nanthini Jayabalan, a senior researcher working on the CNS RRx-001 program in Dr. Gordon’s lab said, "Our review article synthesizes the wealth of data on RRx-001 to date, which supports its disease-modifying potential in a range of conditions."

Added Dr. Gordon: "Emerging evidence suggests, chronic, unresolving inflammation is present in most if not all neurological diseases, and this makes RRx-001 an attractive therapeutic agent for neuroprotection given its track record in human studies."

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

On March 21, 2023 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence ("AI") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that Lantern management and employees will be presenting at three upcoming events:

Rare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET. Panna Sharma, CEO & President, will present.
Session Title: Using AI to Accelerate the Drug Discovery and Development Process for Rare Cancers
Registration Link: https://informaconnect.com/rare-disease-summit/pricing/
How Artificial Intelligence Is Changing Drug Discovery Webinar on Thursday, March 23 at 1:00 p.m. ET. Panna Sharma, CEO & President, will be a panelist. The free webinar is co-hosted by the Science History Institute and the American Chemical Society.
Webinar Link: View Source
Genomics in Precision Oncology Xchange East Coast in Boston, MA on Wednesday, April 5 at 9:05 a.m. ET. Peter Carr, Principal Software Architect, will moderate a session for genomics informed clinical decisions.
Session Title: Clinical trial design & its use in silico modeling for combination therapies
Registration Link: https://www.hub-xchange.com/genomics-in-precision-oncology-east-coast-2023/

RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

On March 21, 2023 RayzeBio, Inc., a targeted radiopharmaceutical company developing innovative cancer drugs, reported the nomination of a first-in-class novel peptide drug candidate against GPC3 (Press release, RayzeBio, MAR 21, 2023, View Source [SID1234629133]). As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy. The proprietary GPC3 targeting agent was discovered through RayzeBio’s research partnership with PeptiDream, Inc. The drug candidate has demonstrated potent and selective GPC3 binding, rapid cellular internalization, and sustained tumor specific uptake and anti-tumor efficacy in preclinical models. Initial preclinical data will be presented at the EASL Liver Cancer Summit in Estoril, Portugal on April 20, 2023.

"Liver cancer represents a significant unmet medical need globally, with over 29,000 deaths annually in the U.S. alone, and over 800,000 deaths worldwide," said Dr. Ken Song, M.D., President and CEO of RayzeBio. "GPC3 is a promising target for radiopharmaceutical therapy. Our discovery team has extensively profiled multiple series of compounds prior to nominating our drug candidate."

RayzeBio is advancing the GPC3 drug candidate into IND enabling studies as a targeted radiopharmaceutical therapy and plans to provide additional details on the program’s progress at various scientific meetings throughout the year. In addition to GPC3, RayzeBio has several other programs in various stages of discovery and development.

About Liver Cancer and Hepatocellular Carcinoma (HCC)

Liver cancer is the third most common cause of cancer death and sixth most diagnosed cancer globally. In the U.S., the incidence of liver cancer more than tripled over the past four decades. The American Cancer Society estimates over 41,000 new cases of liver cancer in 2023 and over 29,000 deaths from liver cancer. The 5-Year relative survival rate for all liver cancer patients is approximately 20% and the survival rate of patients with advanced stage liver cancer is significantly lower. HCC is the most common form of liver cancer, accounting for up to 85% of the cases. HCC represents a significant unmet medical need as current treatment options have limited efficacy with a narrow therapeutic index.